ArticleFrontiers in public health2026
Trends in menopausal hormone therapy use among postmenopausal women in South Korea: analysis of KNHANES 2005-2024.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Menopausal Hormone Therapy (MHT) has long been used to manage postmenopausal symptoms in Republic of Korea. However, long-term trends in MHT use among postmenopausal Korean women remain incompletely characterized. This study examined temporal trends in the lifetime prevalence of MHT use and sociodemographic correlates using nationally representative data spanning two decades. We conducted a secondary analysis of the Korea National Health and Nutrition Examination Survey (KNHANES) cycles 3 (2005), 4 (2007-2009), 5 (2010-2012), and 9 (2024), including 11,407 postmenopausal women aged ≥40 years. Survey-weighted prevalence estimates with 95% confidence intervals were calculated. Rao-Scott chi-square tests assessed differences across survey cycles and demographic subgroups, while survey-weighted logistic regression models evaluated temporal trends. Overall weighted lifetime prevalence of MHT use was 15.0% (95% CI: 14.1-15.9%), increasing significantly from 13.8% in 2005 to 17.5% in 2024 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.